期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Guideline on prevention and treatment of chronic hepatitis B in China (2005) 被引量：44

Guideline on prevention and treatment of chronic hepatitis B in China (2005)
原文传递
导出
摘要 Chronic hepatitis B is one of the most common epidemic diseases in China and has become a majorhealth issue. To help standardize the prevention, diagnosis, and treatment of chronic hepatitis B, the Guideline on prevention and treatment of chronic hepatitis B （abbr. Guideline） was created by a group of appropriate experts belonging to the Society of Hepatology and the Society of Infectious Disease, the Chinese Medical Association according to the principles of evidence-based medicine using the latest clinical research data. The evidence used to formulate the recommendation has been classified into 3 classes and 5 grades, which are indicated by Roman numerals in brackets. Chronic hepatitis B is one of the most common epidemic diseases in China and has become a majorhealth issue. To help standardize the prevention, diagnosis, and treatment of chronic hepatitis B, the Guideline on prevention and treatment of chronic hepatitis B （abbr. Guideline） was created by a group of appropriate experts belonging to the Society of Hepatology and the Society of Infectious Disease, the Chinese Medical Association according to the principles of evidence-based medicine using the latest clinical research data. The evidence used to formulate the recommendation has been classified into 3 classes and 5 grades, which are indicated by Roman numerals in brackets.
作者 Chinese Society of Hepatology,Chinese Medical Association and Chinese Society of Infectious Diseases,Chinese Medical Association
机构地区 Chinese Society of Hepatology
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2007年第24期2159-2173,共15页 中华医学杂志（英文版）
关键词 HBVDNA HBEAG Guideline on prevention and treatment of chronic hepatitis B in China HBsAg HBIG
分类号 R512.6 [医药卫生—内科学]
  • 相关文献

参考文献6

二级参考文献21

  • 1戴志澄 祁国明.中国病毒性肝炎:血清流行病学调查(上卷) (1992-1995)[M].北京:科学技术文献出版社,1997.39-59.
  • 2Shaw T, Locarnini S. Entecavir for the treatment of chronic hepatitis B.Expert Rev Anti Infect ther, 2004, 2:853-871.
  • 3Dienstag JL. The value and limitation of long term nucleoside antiviral therapy in chronic hepatitis B. J Hepatol, 2005, 42: 158-162.
  • 4Chang TT, Hadziyannis S, Ciancian J, et al. Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine therapy. Hepatology, 2002, 36:suppl. Abst 550.
  • 5Tassopoulos N, Hadziyannis S, Ciancian J, et al. Entecavir is superior in treating patients with chronic hepatitis B who have failed lamivudine therapy.Hepatology, 2004, 40: suppl. Abst 673.
  • 6Sherman M, Yurdaydin C, Sollano J, et, al. Entecavir is superior to continued lamivudine for the treatment of lamivudine-refractory, HBeAg ( + )chronic hepatitis B: Results of phase Ⅲ study ETV-026. Hepatology, 2004,40: suppl. Abst 1152.
  • 7Tenny DJ, Levine SM, Rose RE, et al, Clinical emergence of entecavir resistant hepatitis B virus requires additional substitution in virus already resistant to lamivudine. Antimicrob Agent Chemother, 2004, 48:3498-3507.
  • 8Honkoop P, deMan RA. Entecavir: A potent new antiviral drug for hepatitis B. Expert Opin Invest Drug, 2003, 12:683-688.
  • 9Honkoop P, De Man RA. Entecavir: a potent new antiviral drug for hepatitis B. Expert Opin Investig Drugs, 2003, 12: 683-688.
  • 10Seifer M, Hamatake RK, Colonno RJ, et al. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475and lobucavir. Antimicrob Agents Chemother, 1998, 42: 3200-3208.

共引文献674

同被引文献192

引证文献44

二级引证文献393

Chinese Medical Journal
2007年 第24期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部